New drug HWK-016 takes aim at Hard-to-Treat cancers
NCT ID NCT07470853
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new drug called HWK-016 in people with advanced ovarian or endometrial cancers that have not responded to other treatments. The drug is designed to deliver a toxic payload directly to cancer cells that carry a specific marker (MUC16). The main goals are to find the safest dose and to understand side effects. About 265 adults will take part, and some will also receive a second drug called bevacizumab.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Atrium Health - Wake Forest
NOT_YET_RECRUITINGCharlotte, North Carolina, 282204, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Karmanos Cancer Center
NOT_YET_RECRUITINGDetroit, Michigan, 48201, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Memorial Sloan Kettering Cancer Center
NOT_YET_RECRUITINGNew York, New York, 07920, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ohio State University Wexner Medical Center
NOT_YET_RECRUITINGColumbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
SCRI - Florida Cancer Specialists
NOT_YET_RECRUITINGSarasota, Florida, 34232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
SCRI - Mary Crowley Cancer Research
NOT_YET_RECRUITINGDallas, Texas, 75230, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
SCRI - Sydney Kimmel Cancer Center - Jefferson Health
NOT_YET_RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
START - Los Angeles
RECRUITINGLos Angeles, California, 90025, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
START Mountain
RECRUITINGSalt Lake City, Utah, 84119, United States
Contact Phone: •••-•••-••••
-
St. Francis Medical Center (OSF Healthcare)
NOT_YET_RECRUITINGPeoria, Illinois, 61637, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Start - Ny
RECRUITINGLake Success, New York, 11042, United States
Contact Phone: •••-•••-••••
-
University of Arkansas - Winthrop P. Rockefeller Cancer Institute
NOT_YET_RECRUITINGLittle Rock, Arkansas, 72205, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••